SPRY

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is a commercial-stage biotechnology company founded in 2015 and headquartered in San Diego, California. The company went public in December 2020 and has developed a breakthrough needle-free epinephrine treatment for severe allergic reactions. After years of clinical development and regulatory approval processes, ARS successfully launched its flagship product <b>neffy</b> in the United States in September 2024, marking a significant milestone as the first and only needle-free epinephrine treatment approved by the FDA. The company has also secured regulatory approvals in Europe and is expanding globally through strategic partnerships.